Home Cart Sign in  
Chemical Structure| 865854-05-3 Chemical Structure| 865854-05-3
Chemical Structure| 865854-05-3

Tideglusib

CAS No.: 865854-05-3

Tideglusib is an irreversibleGSK-3 inhibitor with IC50 of 5 nM and 60 nM for GSK-3βWT (1 h preincubation) and GSK-3βC199A (1 h preincubation), respectively.

Synonyms: NP031112; NP-12

4.5 *For Research Use Only !

Cat. No.: A140220 Purity: 98%

Change View

Size Price

US Stock

Global Stock

In Stock
1mg łÇǶÊÊ Inquiry Inquiry
10mg łÇÿ¶ÊÊ Inquiry Inquiry
50mg łËď¶ÊÊ Inquiry Inquiry
100mg łÍǶÊÊ Inquiry Inquiry
250mg łòď¶ÊÊ Inquiry Inquiry
1g łÇó˶ÊÊ Inquiry Inquiry
5g łò§ď¶ÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1mg

    łÇǶÊÊ

  • 10mg

    łÇÿ¶ÊÊ

  • 50mg

    łËď¶ÊÊ

  • 100mg

    łÍǶÊÊ

  • 250mg

    łòď¶ÊÊ

  • 1g

    łÇó˶ÊÊ

  • 5g

    łò§ď¶ÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of Tideglusib

CAS No. :865854-05-3
Formula : C19H14N2O2S
M.W : 334.39
SMILES Code : O=C(N1CC2=CC=CC=C2)N(C3=C4C=CC=CC4=CC=C3)SC1=O
Synonyms :
NP031112; NP-12
MDL No. :MFCD18633296
InChI Key :PMJIHLSCWIDGMD-UHFFFAOYSA-N
Pubchem ID :11313622

Safety of Tideglusib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Tideglusib

PI3K-AKT
Hedgehog

Isoform Comparison

Biological Activity

Target
  • GSK-3β

    GSK-3β, IC50:60 nM

In Vitro:

Cell Line
Concentration Treated Time Description Reference
B- and T-cell NHL cell lines 5-10 µM to assess the anti-lymphoma effects and determine the capacity for inducing apoptosis PMC10265916

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05105958 Amyotrophic Lateral Sclerosis PHASE2 NOT_YET_RECRUITING 2026-03-01 University Hospital Bern, Bern... More >>, Switzerland|University Hospital Geneva, Genève, 1205, Switzerland|University Hospital Lausanne, Lausanne, Switzerland|Kantonsspital St. Gallen, Saint-Gall, Switzerland|University Hospital Zurich, Zürich, Switzerland Less <<
NCT02858908 Myotonic Dystrophy 1 PHASE2 COMPLETED 2025-01-18 Newcastle-upon-Tyne Hospitals ... More >>NHS Trust, Newcastle Upon Tyne, Tyne And Wear, NE1 4LP, United Kingdom Less <<
NCT05004129 Congenital Myotonic Dystrophy PHASE2|PHASE3 RECRUITING 2025-03-28 Arkansas Children's Hospital, ... More >>Little Rock, Arkansas, 72202, United States|University of California, Los Angeles (UCLA), Los Angeles, California, 90095, United States|Stanford University, Palo Alto, California, 94304, United States|Lurie's Children's Hospital, Chicago, Illinois, 60611, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, 52242, United States|University of Rochester - Medical Center, Rochester, New York, 14642, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15213, United States|University of Utah Clinical Neurosciences Center, Salt Lake City, Utah, 84132, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, 23507, United States|Virginia Commonwealth University-Department of Neurology - Muscular Dystrophy Translational Research Program, Richmond, Virginia, 23219, United States|The Bright Alliance, Randwick, New South Wales, 2031, Australia|Children's Hospital London Health Sciences Centre (LHSC), London, Ontario, N6A 4G5, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, K1H 8L1, Canada|New Zealand Clinical Research (NZCR), Auckland, 1010, New Zealand Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.99mL

0.60mL

0.30mL

14.95mL

2.99mL

1.50mL

29.91mL

5.98mL

2.99mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories